SGLT2 Inhibitors and Cardiovascular Risk: Lessons Learned From the EMPA-REG OUTCOME Study.
about
Closing the knowledge gap on cardiovascular disease in type 2 diabetes: the EMPA-REG OUTCOME trial and beyondImpact of sodium-glucose cotransporter 2 inhibitors on blood pressureRationale and design of a multicenter placebo-controlled double-blind randomized trial to evaluate the effect of empagliflozin on endothelial function: the EMBLEM trial.Impact of Sodium-Glucose Cotransporter 2 Inhibitors on Nonglycemic Outcomes in Patients with Type 2 Diabetes.Effectiveness of dapagliflozin on vascular endothelial function and glycemic control in patients with early-stage type 2 diabetes mellitus: DEFENCE study.Sodium-Glucose Co-transporter 2 (SGLT2) Inhibitor: Comparing Trial Data and Real-World Use.Getting to the "Heart" of the Matter on Diabetic Cardiovascular Disease: "Thanks for the Memory".Rationale and design of a multicenter randomized controlled study to evaluate the preventive effect of ipragliflozin on carotid atherosclerosis: the PROTECT study.Advances in the management of cardiovascular risk for patients with type 2 diabetes: perspectives from the Academy for Cardiovascular Risk, Outcomes and Safety Studies in Type 2 Diabetes.Effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, on blood pressure and markers of arterial stiffness in patients with type 2 diabetes mellitus: a post hoc analysisSGLT-2 Inhibition with Dapagliflozin Reduces the Activation of the Nlrp3/ASC Inflammasome and Attenuates the Development of Diabetic Cardiomyopathy in Mice with Type 2 Diabetes. Further Augmentation of the Effects with Saxagliptin, a DPP4 Inhibitor.Rationale, Design, and Baseline Characteristics of the Utopia Trial for Preventing Diabetic Atherosclerosis Using an SGLT2 Inhibitor: A Prospective, Randomized, Open-Label, Parallel-Group Comparative Study.Acid-base and electrolyte disorders associated with the use of antidiabetic drugs.The effect of empagliflozin on oxidative nucleic acid modifications in patients with type 2 diabetes: protocol for a randomised, double-blinded, placebo-controlled trial.Implications of the EMPA-REG Trial for Clinical Care and Research.SGLT2 inhibitors in the pipeline for the treatment of diabetes mellitus in Japan.DPP4 inhibitors and cardiovascular outcomes: safety on heart failure.Effect of empagliflozin on cardiac biomarkers in a zebrafish model of heart failure: clues to the EMPA-REG OUTCOME trial?The use of sodium-glucose cotransporter 2 inhibitors in patients with type 2 diabetes and hypertension: a focus on African-American populations.SGLT2 Inhibitors: Benefit/Risk Balance.Sodium-glucose cotransporter 2 inhibition and health benefits: The Robin Hood effect.Evaluation of the pharmacokinetics, pharmacodynamics and clinical efficacy of empagliflozin for the treatment of type 2 diabetes.Effects of sodium-glucose co-transporter 2 inhibitors on metabolism: unanswered questions and controversies.Empagliflozin: Role in Treatment Options for Patients with Type 2 Diabetes Mellitus.Blood pressure reduction in diabetes: lessons from ACCORD, SPRINT and EMPA-REG OUTCOME.Evaluating the costs of glycemic response with canagliflozin versus dapagliflozin and empagliflozin as add-on to metformin in patients with type 2 diabetes mellitus in the United Arab Emirates.Metabolic Recovery of the Failing Heart: Emerging Therapeutic Options.A consensus statement for the clinical use of the renal sodium-glucose co-transporter-2 inhibitor dapagliflozin in patients with type 2 diabetes mellitus.Combination therapy with GLP-1 receptor agonist and SGLT2 inhibitor.Role of sodium glucose cotransporter-2 inhibitors in type I diabetes mellitus.Considerations and treatment options for patients with comorbid atrial fibrillation and diabetes mellitus.Heart failure hospitalization risk associated with use of two classes of oral antidiabetic medications: an observational, real-world analysis.Cardiovascular benefits of the newer medications for treating type 2 diabetes mellitusEmpagliflozin: Novel antidiabetes and pro-cardiac drug.Partitioning of adipose lipid metabolism by altered expression and function of PPAR isoforms after bariatric surgery.Dapagliflozin Enhances Fat Oxidation and Ketone Production in Patients With Type 2 Diabetes.Real-world use and modeled impact of glucose-lowering therapies evaluated in recent cardiovascular outcomes trials: An NCDR® Research to Practice project.Extracellular Vesicles as Protagonists of Diabetic Cardiovascular Pathology.Direct cardiovascular impact of SGLT2 inhibitors: mechanisms and effects.Cardiovascular Disease and Type 2 Diabetes: Has the Dawn of a New Era Arrived?
P2860
Q28075848-D5055209-64AA-48A0-AA21-F7287022AE35Q28080114-B795933E-059E-4F70-AD7B-BA0ECA9E5B28Q33556240-9AE1B683-E4E8-4B01-A73C-949CFA2F5BBAQ33625568-E7221985-2113-40A3-AA5B-857C42C9539EQ33882438-ED4440BE-C9F3-49A9-9E82-BBDCCC11930EQ36316732-BBB8247E-5594-4EA4-8360-70DF1F422CFAQ37237432-06944BFB-C43D-4237-B4FD-452889CC0B53Q37251449-813E399B-6FD8-46CB-8BDD-A0A5378A3758Q37594479-88AC05A2-9E35-4AD9-8121-847E9D8B8E0CQ37668253-CCF224D3-FD51-4C00-90F4-A842457DC328Q38288267-6248126C-9FDD-415F-8B00-29376D8F1CC8Q38597063-86EAAE52-6368-41DB-B383-1E4548677217Q38658251-9B25BC16-B154-415D-9A28-938AD83E1EBAQ38793748-C4D7A8BC-889E-4F95-8A59-DA40ACE07465Q38798623-45062B3C-C049-4E12-80C4-79361477EB62Q38824557-3F9542E8-D716-49E0-B667-D65E4617D8F1Q38833312-C3D591DD-3AE6-4821-8D2C-A44D2E13564DQ38845967-AF0371E1-B5DD-424D-81E5-1FCE3F0710EEQ38870752-97724F33-1678-4349-81E0-A52FB3E6AB2AQ38931842-F384CEEB-F047-409F-A519-05AF1D01C00DQ38978384-AC5E11A0-333D-4886-B244-20EC699F6B9FQ39000172-91BA649A-04F0-48CB-8D00-A91E507244ECQ39000587-F5A66356-AC88-4884-BCEF-68D7CD2A9BA2Q39006105-32F610A9-FBA1-4D6C-A7AB-236E666B1D0DQ39096331-CBF42B5A-77C9-481D-9CC7-7948E9BAA116Q39190208-8C40F1FC-5E83-4F74-8976-5B45A09781B3Q39245449-4E62BADD-C9F6-4D43-BCC4-74FA9D9AE050Q39255188-B28CF7DF-61C8-4F8F-AA62-58B6FC8B9491Q39255963-A70A6148-A8C0-4270-A4CE-65D5BFC5D342Q39300071-443E6481-7A17-4220-9AC5-3E4804483E4BQ39409421-EC1D8F09-43D6-4D7E-BD54-E1F6CA0E6BF0Q41176211-6769744E-8005-4423-8EDD-A177F91080F6Q41242150-CC49EB30-622D-42CE-9919-26A893F28F27Q42245609-1BB66980-3BE5-4C27-9528-F1261CE68340Q42697143-D8B8B06E-E0FE-4464-9A9A-4C4E86624F41Q42718201-C743548B-2E12-48AC-B741-4E7B06814A2EQ46348934-1A7C8B4B-61AB-49F6-AAAB-349A32E58ED4Q47138160-A545A635-2132-4142-B0FF-265748F3B8E6Q47739163-3D96C5AC-9CB6-4054-BC0C-FAA79664A9A0Q47849041-8A6EBA79-0C94-443E-AD49-6FAD0E74FD56
P2860
SGLT2 Inhibitors and Cardiovascular Risk: Lessons Learned From the EMPA-REG OUTCOME Study.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
SGLT2 Inhibitors and Cardiovas ...... om the EMPA-REG OUTCOME Study.
@en
type
label
SGLT2 Inhibitors and Cardiovas ...... om the EMPA-REG OUTCOME Study.
@en
prefLabel
SGLT2 Inhibitors and Cardiovas ...... om the EMPA-REG OUTCOME Study.
@en
P2093
P2860
P356
P1433
P1476
SGLT2 Inhibitors and Cardiovas ...... om the EMPA-REG OUTCOME Study.
@en
P2093
Muhammad Abdul-Ghani
Robert Chilton
Stefano Del Prato
P2860
P304
P356
10.2337/DC16-0041
P407
P577
2016-05-01T00:00:00Z